atorvastatin has been researched along with Androgen-Independent Prostatic Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexander, L; Delles, C; Hedley, A; Jones, R; Leung, HY; Loveridge, C; MacLeod, M; McCartney, E; Mui, E; Neilson, M; Patel, R; Rushworth, LK; Salji, M; Sumpton, D; Wallace, J | 1 |
| Dwi Cahyadi, D; Irie, N; Ishikawa, T; Sugiura, A; Tashiro, J; Warita, K; Warita, T | 1 |
1 trial(s) available for atorvastatin and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Phase II proof-of-concept study of atorvastatin in castration-resistant prostate cancer.
Topics: Androgen Antagonists; Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Tryptophan | 2023 |
1 other study(ies) available for atorvastatin and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
CYP11A1 silencing suppresses HMGCR expression via cholesterol accumulation and sensitizes CRPC cell line DU-145 to atorvastatin.
Topics: Atorvastatin; Cell Line, Tumor; Cholesterol; Cholesterol Side-Chain Cleavage Enzyme; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ketoconazole; Male; Prostatic Neoplasms, Castration-Resistant | 2023 |